NASDAQ:ETNB 89BIO Q3 2025 Earnings Report Profile 89BIO EPS ResultsActual EPSN/AConsensus EPS -$0.50Beat/MissN/AOne Year Ago EPSN/A89BIO Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/A89BIO Announcement DetailsQuarterQ3 2025Date11/6/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesCompany Profile 89BIO Earnings HeadlinesBiotech stocks are coming back. Here’s what will drive the sector higher.November 3, 2025 | msn.com89bio Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNBOctober 6, 2025 | businesswire.comElon’s Biggest Launch Ever: 15x Bigger Than SpaceXThe Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked America's #1 stock picker in 2020. He was mentored by two hedge fund billionaires from the Soros network and trained at Caltech. His readers have had the chance to see gains as high as AMD +8,500%... Nvidia +5,000%... Tesla +3,500%... Palantir +1,000%... and Apple +890%.May 8 at 1:00 AM | InvestorPlace (Ad)Assessing 89bio (ETNB) Valuation Following a 60% Share Price RallyOctober 2, 2025 | finance.yahoo.com89bio, Inc. (ETNB) Shareholders to Receive Up to $3.5B Total in Roche Buyout DealSeptember 30, 2025 | msn.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of 89bio, Inc. (NASDAQ: ETNB)September 23, 2025 | prnewswire.comSee More 89BIO Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like 89BIO? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 89BIO and other key companies, straight to your email. Email Address About 89BIO89BIO (NASDAQ:ETNB), Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for metabolic and endocrine disorders. The company’s lead investigational asset, BIO89-100 (pegozafermin), is a long-acting analog of fibroblast growth factor 21 (FGF21) designed to address underlying drivers of nonalcoholic steatohepatitis (NASH), severe hypertriglyceridemia and related metabolic diseases. By leveraging protein engineering and proprietary delivery technologies, 89bio aims to improve metabolic health through targeted modulation of lipid and glucose pathways. In addition to its NASH program, 89bio is exploring indications that include glycogen storage disease and other rare metabolic conditions with high unmet medical need. The company has advanced BIO89-100 into multiple clinical trials across North America and Europe, generating safety and efficacy data to support potential regulatory filings. Its research and development efforts are complemented by collaborations with academic centers and contract research organizations to accelerate patient enrollment and expand the understanding of FGF21 biology. Headquartered in Redwood City, California, 89bio was founded in 2018 and completed its initial public offering on the NASDAQ under the ticker ETNB in 2022. Under the leadership of Chief Executive Officer Arndt Zhang, the company is building a pipeline of endocrine therapies aimed at transforming the treatment landscape for patients with chronic metabolic diseases.View 89BIO ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality CheckThe AI Fear Around Datadog Stock May Have Been Completely WrongAmprius Technologies Ups the Voltage on Forward OutlookWhy Lam Research Still Looks Like a Buy After a 300% RallyIonQ Just Posted a Breakout Quarter—But 1 Problem RemainsSLB’s Tough Quarter Masks a Powerful Long-Term ShiftSuper Micro Surges Over 20% as Margins Soar, Sales Fall Short Upcoming Earnings Constellation Energy (5/11/2026)Barrick Mining (5/11/2026)Petroleo Brasileiro S.A.- Petrobras (5/11/2026)Simon Property Group (5/11/2026)SEA (5/12/2026)Cisco Systems (5/13/2026)Alibaba Group (5/13/2026)Manulife Financial (5/13/2026)Sumitomo Mitsui Financial Group (5/13/2026)Takeda Pharmaceutical (5/13/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
